drugset / Trial / NCT01162421

A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis

NCT01162421

Phase 4 Completed 77 enrolled AbbVie Mount Sinai Hospital, Canada · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more participants when introduced earlier than in current practice.

Timeline

Start
2010-09
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Background Methotrexate Small molecule

Indications